A phase 3, open-label, controlled, randomized, multicenter trial evaluating the efficacy and safety of StrataGraft® construct in patients with deep partial-thickness thermal burns
Open Access
Abstract
No abstract availableKeywords
Funding Information
- BARDA
- Mallinckrodt Pharmaceuticals
This publication has 13 references indexed in Scilit:
- Sensitization and desensitization of burn patients as potential candidates for vascularized composite allotransplantationBurns, 2016
- Anti-HLA sensitization in extensively burned patients: extent, associated factors, and reduction in potential access to vascularized composite allotransplantationTransplant International, 2015
- Management of the Skin and Soft Tissue in the Geriatric Surgical PatientSurgical Clinics of North America, 2015
- Biological therapies for the treatment of cutaneous wounds: Phase III and launched therapiesExpert Opinion on Biological Therapy, 2013
- Factors Affecting Wound HealingJournal of Dental Research, 2010
- The Patient and Observer Scar Assessment Scale: A Reliable and Feasible Tool for Scar EvaluationPlastic and Reconstructive Surgery, 2004
- Multicenter Postapproval Clinical Trial of Integra® Dermal Regeneration Template for Burn TreatmentJournal of Burn Care & Rehabilitation, 2003
- Thickness and Echogenicity of the Skin in Children as Assessed by 20-MHz UltrasoundDermatology, 2000
- Normal Growth and Differentiation in a Spontaneously Immortalized Near-Diploid Human Keratinocyte Cell Line, NIKSJournal of Investigative Dermatology, 2000
- THE BURN WOUND FROM THE SURGICAL POINT OF VIEW1975